IOncology

At the 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO), during the Infectious Tumors Subcommittee session, Dr. Qingbo Wang from The Second Hospital of Nanjing presented a report titled "Comprehensive Treatment Strategies for Tuberculosis-Associated Lung Cancer." The presentation explored the epidemiology, diagnostic challenges, and treatment strategies for patients with coexisting tuberculosis (TB) and lung cancer.

The historic city of Xi’an became a gathering place for top global oncologists as the 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO) and the Asian Oncology Socitey (AOS) took place from November 14 to 17. This event symbolized a significant integration of the global oncology community. During the gynecologic oncology session at CCHIO, Dr. Xiaohua Wu from Fudan University Shanghai Cancer Center delivered a presentation titled "Enhancing Preoperative Evaluation Strategies for Advanced Ovarian Cancer Patients." In an exclusive interview with Oncology Frontier, he shared Fudan's experience in advancing preoperative evaluation methods for ovarian cancer.

The era of targeted immunotherapy has revolutionized liver cancer treatment, offering unprecedented therapeutic efficacy. Comprehensive approaches are emerging to enhance patient outcomes, prompting a reevaluation of traditional surgical concepts for liver cancer.

With advancements in local treatment techniques and the emergence of new therapeutic agents, combined local and systemic therapies have demonstrated synergistic effects greater than the sum of their parts in liver cancer management. For patients with intermediate and advanced liver cancer, this approach has improved conversion therapy success rates and even achieved curative outcomes. At the 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO), during the "Interventional Oncology" session, Dr. Ming Zhao from the Sun Yat-sen University Cancer Center shared his insights on the combined treatment approach. Oncology Frontier interviewed Professor Zhao to discuss the theoretical foundations, current developments, and future directions of combined local and systemic therapies.

In the historic city of Xi'an, renowned for its cultural significance, the 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO) and the Asian Oncology Society (AOS) took place from November 14 to 17, creating a global platform for the oncology community. During the CCHIO’s gynecological oncology session, Dr. Jianqing Zhu from Zhejiang Cancer Hospital presented her report on "Precision Diagnosis and Treatment of Platinum-Resistant Recurrent Ovarian Cancer."

The 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO) opened grandly in the ancient city of Xi’an on November 16, focusing on the theme "Winning Against Cancer Through Integration." This conference brought together global medical elites to strategize for global health solutions. During the event, conference chair and President of the China Anti-Cancer Association (CACA), Academician Daiming Fan, shared insights in an interview with Oncology Frontier. He delved into the pivotal role of integrative medicine in advancing global medical progress and its profound impact on the future of healthcare.

From November 14 to 17, 2024, the Cellular Therapy and Immunotherapy (CTI) Conference was held in Hangzhou, China, bringing together leading global experts, scholars, and industry leaders in the field of cell and immunotherapy. This conference served not only as a platform for academic exchange but also as a vital window to showcase cutting-edge research and drive advancements in the field. Dr. Peihua Lu, a pioneer in CAR-T clinical trials and a leader at Beijing Lu Daopei Hospital, shared groundbreaking progress on CAR-T therapies for T-cell malignancies at CTI 2024, following earlier presentations on CD7 CAR-T therapy for T-ALL/LBL at The twelfth annual meeting of the Society of Hematologic Oncology (SOHO 2024)  meeting. In an exclusive interview with Hematology Frontier, Professor Lu discussed strategies for applying CAR-T therapy across different types and stages of T-cell malignancies, China’s role in global CAR-T research, and the importance of international collaboration.

The 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO) and the 4th Asian Oncology Society (AOS), hosted by the China Anti-Cancer Association (CACA), and co-organized by the Institute for Development Strategy of Holistic Integrative Medicine and Shaanxi Anti-Cancer Association, was grandly held in the ancient capital of Xi'an from November 14th to 17th. During this conference, CACA joined hands with several global academic groups in cancer prevention and treatment, including the Union for International Cancer Control (UICC), the Latin American and Caribbean Society of Medical Oncology (SLACOM), the National Comprehensive Cancer Network (NCCN), the Senologic International Society (SIS), and the London Global Cancer Week (LGCW), to hold special summits, enhancing the friendship among Chinese and international peers in cancer prevention and treatment, and is expected to promote more cooperation and exchange. Connecting hearts across continents, planning for development. On the morning of November 17th, the CHINA-AFRICA and CACA-LGCW summits attracted international experts and scholars from China, Africa, Europe, and other places, focusing on the global perspective and achievements in cancer treatment, as well as the progress and challenges in cancer research and treatment.

In the battle against breast cancer, every physician is a bold explorer, extending the boundaries of life through innovation and dedication. Their efforts not only save lives in the clinic but also drive progress in research, contributing to more precise and effective treatments for breast cancer patients. During the 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO), Oncology Frontier interviewed Dr. Wenxing Qin from Fudan University Shanghai Cancer Center. Professor Qin shared insights into the latest advancements in breast cancer research and treatment, as well as his experience attending the CCHIO. With profound clinical expertise and sharp scientific acumen, he discussed breakthroughs in molecular profiling and personalized treatment strategies for refractory breast cancer, shedding light on future directions in the field.